MSF Expert Client performing a HIV test at the MSF Dipping Tank community testing campaign at Nhletsheni, in Shiselweleni region, south of Swaziland.
Report series

Untangling the Web of Antiretroviral Price Reductions

HIV/AIDS
Photograph by Giorgos Moutafis
MSF Expert Client performing a HIV test at the MSF Dipping Tank community testing campaign at Nhletsheni, in Shiselweleni region, south of Swaziland. Photograph by Giorgos Moutafis

For more than 20 years, the MSF Access Campaign has been monitoring the patent barriers, prices and availability of antiretroviral medicines (ARV) through its Untangling the Web report series and pushing for the uptake of policies that promote access to affordable, quality-assured treatments.

While more people with HIV are receiving antiretroviral treatment (ART) than ever before, persistent and deadly gaps in the global response to HIV/AIDS continue to undermine progress against the epidemic. By the end of 2019, 25 million people had access to ART, but this represents just 67% of the 38 million people living with HIV, leaving a deadly gap of more than 12 million people in need of treatment.

The latest report in the series, continues the analyses of access barriers to affordable, lifesaving diagnostics and treatments for HIV and opportunistic infections. Updated drug pricing information is also provided.

All editions